MARKSANS PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 172.2 INR | +2.99% |
|
-1.23% | +6.86% |
| Apr. 18 | Marksans Pharma's Goa Facility Gets Five Inspectional Observations from US FDA | MT |
| Feb. 14 | Transcript : Marksans Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024 |
Valuation
| Fiscal Period: März | 2019 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 10,212 | 31,903 | 78,012 | - |
| Enterprise Value (EV) 1 | 10,212 | 31,903 | 78,012 | 78,012 |
| P/E ratio | 13.3 x | 11 x | 23.4 x | 19.2 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 1.02 x | - | 3.61 x | 2.96 x |
| EV / Revenue | 1.02 x | - | 3.61 x | 2.96 x |
| EV / EBITDA | 7.47 x | - | 14.9 x | 12.4 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | 3.75 x | 3.14 x |
| Nbr of stocks (in thousands) | 409,314 | 453,164 | 453,164 | - |
| Reference price 2 | 24.95 | 70.40 | 172.2 | 172.2 |
| Announcement Date | 5/29/19 | 5/30/23 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2019 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | 10,001 | - | 21,583 | 26,332 |
| EBITDA 1 | 1,368 | - | 5,229 | 6,305 |
| EBIT | - | - | - | - |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | 4,490 | 5,468 |
| Net income 1 | 804.4 | 2,653 | 3,335 | 4,066 |
| Net margin | 8.04% | - | 15.45% | 15.44% |
| EPS 2 | 1.870 | 6.410 | 7.360 | 8.970 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 5/29/19 | 5/30/23 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2024 Q3 |
|---|---|
| Net sales 1 | 5,525 |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) 1 | 1,179 |
| Net income 1 | 865 |
| Net margin | 15.66% |
| EPS 2 | 1.910 |
| Dividend per Share | - |
| Announcement Date | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | 15.9% | - | 16% | 16% |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share 2 | - | - | 45.90 | 54.80 |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 5/29/19 | 5/30/23 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
172.2
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +6.86% | 935M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- MARKSANS Stock
- Financials Marksans Pharma Limited
